Cortex
Quince Therapeutics (formerly Cortexyme, Inc.) is a clinical-stage biopharmaceutical company focused on developing therapeutic approaches to treat rare degenerative diseases. The company rebranded in August 2022 following its acquisition of Novosteo, a biotech focused on rare skeletal diseases and bone cancer treatment. Quince went public in May 2019 on NASDAQ under ticker CRTX (later changed to QNCX) and is currently exploring strategic alternatives following a Phase 3 trial failure in January 2026.
Public Company
Cortex is publicly traded
IPO'd on May 9, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under CRTX.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Total Funding
$112.5M
4 rounds
Last Private Valuation
$0.47B
Sep 4, 2024
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
2 signalsBoard approved Orphai's Brigette Roberts to succeed Dirk Thye as CEO, contingent on stockholder vote now set for Oct 6, 2026
Operational control shifting to acquired Orphai team once financing/share-issuance votes pass
Closed reverse-merger acquisition of Orphai Therapeutics; legacy holders diluted to ~6.9% fully diluted post-financing
Change-of-control resets the cap table; pipeline and story now pulmonary-disease, not rare degenerative disease
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $112.5M across 4 rounds
Last updated 09-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Sep 4, 2024 | Series C | $60M | $0.47B | Scale Venture Partners |
| May 31, 2023 | Series B TechCrunch | $35M | — | IVP |
| 2021 | Series A | $15M | — | Tiger Global, Sequoia Capital |
Prominent Investors
Leadership
Dirk Thye
Chief Executive Officer
Charles Ryan
President
Cortex Investment FAQ
Cortex FAQ
Yes, Cortex is publicly traded under the ticker symbol CRTX on the NASDAQ. The company went public in May 9, 2019.
Cortex trades under the ticker symbol CRTX on the NASDAQ. It began trading in May 9, 2019.
Cortex (CRTX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CRTX to place an order.
Cortex went public in May 9, 2019 via ipo, with an offering valuation of approximately $0.47B. Quince Therapeutics (ticker QNCX, formerly CRTX) went public on NASDAQ on May 9, 2019. As of February 2026, the company received Nasdaq deficiency notices for failing to meet minimum bid price ($1.00) and market value requirements, with imminent delisting risk. The company is exploring strategic alternatives, including a potential reverse merger, following a Phase 3 trial failure for its lead candidate eDSP in January 2026. Financial distress: sub-$6M cash, ~$12M short-term investments, >$16M EIB credit line at year-end 2025. Company warned of potential liquidation or bankruptcy if suitable strategic transaction not completed.
Cortex raised $112.5M across 4 disclosed funding rounds prior to its public listing.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.